Limits...
Effectiveness of the AS03-adjuvanted vaccine against pandemic influenza virus A/(H1N1) 2009--a comparison of two methods; Germany, 2009/10.

Uphoff H, An der Heiden M, Schweiger B, Campe H, Beier D, Helmeke C, Littmann M, Haas W, Buda S, Faensen D, Feig M, Altmann D, Wichmann O, Eckmanns T, Buchholz U - PLoS ONE (2011)

Bottom Line: The authors compared results of two methods calculating the effectiveness of the vaccine (VE).VE in the two methods was 79% (95% confidence interval (CI) = 35-93%; P = 0.007) and 87% (95% CI = 78-92%; P<0.001) for individuals less than 14 years of age and 70% (95% CI = -45%-94%, P = 0.13) and 74% (95% CI = 64-82%; P<0.001) for individuals above the age of 14.Both methods yielded similar VE in both age groups; and VE for the younger age group seemed to be higher.

View Article: PubMed Central - PubMed

Affiliation: Hessisches Landes Prüfungs - und Untersuchungsamt im Gesundheitswesen, Dillenburg, Germany. h.uphoff@hlpug.hessen.de

ABSTRACT
During the autumn wave of the pandemic influenza virus A/(H1N1) 2009 (pIV) the German population was offered an AS03-adjuvanted vaccine. The authors compared results of two methods calculating the effectiveness of the vaccine (VE). The test-negative case-control method used data from virologic surveillance including influenza-positive and negative patients. An innovative case-series methodology explored data from all nationally reported laboratory-confirmed influenza cases. The proportion of reported cases occurring in vaccinees during an assumed unprotected phase after vaccination was compared with that occurring in vaccinees during their assumed protected phase. The test-negative case-control method included 1,749 pIV cases and 2,087 influenza test-negative individuals of whom 6 (0.3%) and 36 (1.7%), respectively, were vaccinated. The case series method included data from 73,280 cases. VE in the two methods was 79% (95% confidence interval (CI) = 35-93%; P = 0.007) and 87% (95% CI = 78-92%; P<0.001) for individuals less than 14 years of age and 70% (95% CI = -45%-94%, P = 0.13) and 74% (95% CI = 64-82%; P<0.001) for individuals above the age of 14. Both methods yielded similar VE in both age groups; and VE for the younger age group seemed to be higher.

Show MeSH

Related in: MedlinePlus

Vaccinated cases by time between vaccination and Illness.Frequency of reported and vaccinated laboratory-confirmed cases of pandemic influenza H1N1(2009) by interval between vaccination and illness onset; weeks of illness onset 44–53/2009; Germany.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3138735&req=5

pone-0019932-g003: Vaccinated cases by time between vaccination and Illness.Frequency of reported and vaccinated laboratory-confirmed cases of pandemic influenza H1N1(2009) by interval between vaccination and illness onset; weeks of illness onset 44–53/2009; Germany.

Mentions: In the period from week 44/2009 to week 53/2009 102,454 cases with a known date of illness onset and age were reported. Of these, vaccination status was known for 73,280 cases (71%). The number of vaccinated cases by interval between vaccination date and illness onset started with a peak on the first day after vaccination and decreased then rapidly to very low numbers by day 10–14 (Fig. 3). The distribution of the number of vaccinated cases by age group was bimodal with one peak at the age group 11–15 years and a second at 46–50 years. Figure 4 shows the total number of cases by week of illness onset as well as the number of vaccinated cases by week of vaccination. The shape of the curve of vaccinated cases by week of vaccination is similar to that of the number of reported cases. The expected number of vaccinated cases during their protected period (assuming that VE is 0%) differs markedly from the curve with the actual number of vaccinated cases during the protected period (Fig. 4).


Effectiveness of the AS03-adjuvanted vaccine against pandemic influenza virus A/(H1N1) 2009--a comparison of two methods; Germany, 2009/10.

Uphoff H, An der Heiden M, Schweiger B, Campe H, Beier D, Helmeke C, Littmann M, Haas W, Buda S, Faensen D, Feig M, Altmann D, Wichmann O, Eckmanns T, Buchholz U - PLoS ONE (2011)

Vaccinated cases by time between vaccination and Illness.Frequency of reported and vaccinated laboratory-confirmed cases of pandemic influenza H1N1(2009) by interval between vaccination and illness onset; weeks of illness onset 44–53/2009; Germany.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3138735&req=5

pone-0019932-g003: Vaccinated cases by time between vaccination and Illness.Frequency of reported and vaccinated laboratory-confirmed cases of pandemic influenza H1N1(2009) by interval between vaccination and illness onset; weeks of illness onset 44–53/2009; Germany.
Mentions: In the period from week 44/2009 to week 53/2009 102,454 cases with a known date of illness onset and age were reported. Of these, vaccination status was known for 73,280 cases (71%). The number of vaccinated cases by interval between vaccination date and illness onset started with a peak on the first day after vaccination and decreased then rapidly to very low numbers by day 10–14 (Fig. 3). The distribution of the number of vaccinated cases by age group was bimodal with one peak at the age group 11–15 years and a second at 46–50 years. Figure 4 shows the total number of cases by week of illness onset as well as the number of vaccinated cases by week of vaccination. The shape of the curve of vaccinated cases by week of vaccination is similar to that of the number of reported cases. The expected number of vaccinated cases during their protected period (assuming that VE is 0%) differs markedly from the curve with the actual number of vaccinated cases during the protected period (Fig. 4).

Bottom Line: The authors compared results of two methods calculating the effectiveness of the vaccine (VE).VE in the two methods was 79% (95% confidence interval (CI) = 35-93%; P = 0.007) and 87% (95% CI = 78-92%; P<0.001) for individuals less than 14 years of age and 70% (95% CI = -45%-94%, P = 0.13) and 74% (95% CI = 64-82%; P<0.001) for individuals above the age of 14.Both methods yielded similar VE in both age groups; and VE for the younger age group seemed to be higher.

View Article: PubMed Central - PubMed

Affiliation: Hessisches Landes Prüfungs - und Untersuchungsamt im Gesundheitswesen, Dillenburg, Germany. h.uphoff@hlpug.hessen.de

ABSTRACT
During the autumn wave of the pandemic influenza virus A/(H1N1) 2009 (pIV) the German population was offered an AS03-adjuvanted vaccine. The authors compared results of two methods calculating the effectiveness of the vaccine (VE). The test-negative case-control method used data from virologic surveillance including influenza-positive and negative patients. An innovative case-series methodology explored data from all nationally reported laboratory-confirmed influenza cases. The proportion of reported cases occurring in vaccinees during an assumed unprotected phase after vaccination was compared with that occurring in vaccinees during their assumed protected phase. The test-negative case-control method included 1,749 pIV cases and 2,087 influenza test-negative individuals of whom 6 (0.3%) and 36 (1.7%), respectively, were vaccinated. The case series method included data from 73,280 cases. VE in the two methods was 79% (95% confidence interval (CI) = 35-93%; P = 0.007) and 87% (95% CI = 78-92%; P<0.001) for individuals less than 14 years of age and 70% (95% CI = -45%-94%, P = 0.13) and 74% (95% CI = 64-82%; P<0.001) for individuals above the age of 14. Both methods yielded similar VE in both age groups; and VE for the younger age group seemed to be higher.

Show MeSH
Related in: MedlinePlus